首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1903790

全球MYC标靶疗法市场：市场机会、标靶策略、技术开发平台及临床试验展望（2026年）

Global MYC Targeting Therapies Market Opportunity, Targeting Approaches, Technology Development Platforms & Clinical Trials Insight 2026

出版日期: 2026年01月01日 | 出版商:

KuicK Research | 英文 120 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球MYC标靶疗法市场 - 市场机会、标靶策略、技术开发平台及临床试验展望（2026年） - 发现与亮点

预计首个MYC标靶疗法将于2030年前获批
全球MYC标靶疗法市场机会展望
MYC标靶疗法临床试验的全面洞察：超过10种疗法
按公司、国家、适应症和阶段划分的MYC标靶药物临床试验洞察
依公司划分的MYC标靶疗法开发平台：超过5种标靶平台
MYC标靶疗法临床试验的启动日期和预计完成日期适应症
竞争格局

MYC标靶疗法的需求及本报告的意义

MYC标靶疗法的科学和商业格局正从概念探索阶段过渡到具有可量化早期进展的结构化开发项目。随着越来越多的公司寻求将MYC生物学转化为实用的治疗方法，决策者需要超越科学复杂性的清晰可靠的资讯。本报告旨在满足此需求。

MYC仍然是癌症生物学中最重要的致癌驱动因子之一，它影响多种肿瘤类型的细胞增殖、代谢、压力反应和存活机制。由于MYC是许多致癌路径的核心，因此能够安全改变其活性的疗法有望得到广泛的临床应用。然而，这项机会也伴随着技术挑战。 MYC深度整合于调控网络中，具有高度动态性，且结构复杂。因此，随着该领域的发展势头强劲，需要专门的报告来帮助利害关係人了解不断变化的竞争格局，解读企业所采取的科学策略，并为合作和投资做好准备。

本报告提供策略视角，涵盖最相关的数据，包括研发管线、合作伙伴关係、技术平台、地理布局、临床策略和竞争优势，旨在帮助企业儘早进入这个未来几年有望显着增长的市场。

本报告包含临床试验洞察

本报告系统而详细地概述了处于临床前和临床开发阶段的候选MYC靶向化合物。虽然目前处于人体试验阶段的化合物数量仍然很高，但相关活动正在增加，计画也正进入更成熟的阶段。试验遍及美国、欧洲、中国和澳洲等主要地区，涵盖了MYC扩增、过度表现或路径依赖性尤为突出的多种适应症。

本报告深入探讨了开发人员如何应对调控主调控因子所固有的高风险，包括治疗环境、分子模式、生物标记策略和试验设计的考量。此外，报告还介绍了在推进早期转化研究方面发挥关键作用的机构赞助商、学术合作者和技术授权者。由于 MYC 生物学具有高度的背景依赖性，这些试验层面的细节可以帮助利害关係人评估哪些方法在临床上最一致且在商业上最可行。

透过将分散的试验资讯整合到一个统一的结构中，本报告有助于更深入地了解全球 MYC 标靶治疗领域的成熟度、进展速度和潜在的转折点。

参与 MYC 标靶治疗研发的主要公司

目前，这个充满活力的领域得到了成熟创新者和新兴生技公司的共同支持。儘管目前已采用多种策略，包括直接抑制剂、降解促进剂、转录调节剂以及基于RNA/寡核苷酸的技术，但其共同目标是在最大限度降低毒性的同时，精准抑制MYC活性。

根据这份报告，开发结构导向抑制剂、MYC/MAX破坏剂、标靶蛋白降解剂、合成致死策略以及用于细胞内转录因子的下一代递送平台的公司，对市场的影响最大。这些公司正在迅速建立合作伙伴关係，以加速技术转移、确保平台技术的安全性并开发概念验证资料集。

由于该领域仍处于早期阶段，投资者、合作伙伴和竞争对手需要了解哪些公司拥有深厚的科学实力、可扩展的平台以及差异化的战略地位。

本报告涵盖的技术平台

本报告的一个关键章节重点介绍了支持MYC标靶药物开发的底层技术。一个特别值得关注的平台是快速发展的以蛋白质为中心和以结构为导向的治疗模式。这些模式旨在靶向固有无序蛋白（IDP），包括MYC。传统药物设计一直难以有效标靶IDP。

例如，先进的胜肽模拟系统和标靶降解技术已展现出在破坏MYC复合物稳定性、改变其构象状态以及调节蛋白质在DNA上的滞留方面的巨大潜力。这为开发能够直接与MYC相互作用的药物奠定了基础，而不仅仅依赖通路层面的调控。

透过系统地梳理这些技术组成部分，本报告清楚地阐明了推动研发管线成长和竞争差异化的技术引擎。

一份描绘MYC标靶治疗领域未来发展方向的报告

随着MYC标靶治疗的不断深入，该领域应朝着精准的患者分层、多样化的治疗模式、联合治疗策略以及更深入的生物学图谱构建方向发展。儘管MYC标靶疗法尚未商业化，但首次人体临床试验的早期成功以及不断增长的投资正在重塑未来十年的格局。

本报告概述了影响市场成熟度的发展趋势、合作机会和科学转折点。随着MYC标靶疗法稳步迈向临床和商业化应用，本报告提供了一个前瞻性的分析框架，帮助利害关係人驾驭这一复杂但快速发展的治疗领域，从而掌握其发展历程中的关键时刻。

First MYC Targeting Therapy Approval Expected By 2030
Global MYC Targeting Therapies Market Opportunity Outlook
Comprehensive Insight On MYC Targeting Therapies In Clinical Trials: > 10 Therapies
MYC Targeting Drugs Clinical Trials Insight By Company, Country, Indication & Phase
MYC Targeting Therapies Development Platforms By Companies: > 5 Targeting Platforms
MYC Targeting Therapies Clinical Studies Start & Expected Completion Timeline By Indication
Competitive Landscape

MYC Targeted Therapies Need & Why This Report?

Concept exploration is giving way to structured development programs with quantifiable early stage progress in the scientific and commercial landscape for MYC targeted therapies. Decision makers need clear, reliable information that cuts through scientific complexity as more companies try to convert MYC biology into practical therapeutic approaches. The purpose of this report is to address that need.

With effects on cellular proliferation, metabolism, stress response, and survival mechanisms across a variety of tumor types, MYC continues to be one of the most important oncogenic drivers in cancer biology. Since MYC is at the core of numerous oncogenic circuits, any treatment that can safely alter its activity may have a wide range of clinical applications. However, this opportunity is accompanied by technical challenges: MYC is deeply ingrained in regulatory networks, highly dynamic, and structurally elusive. Therefore, at a time when the field is gaining momentum, a specialized report is necessary to assist stakeholders in comprehending the developing competitive environment, interpreting the scientific strategies companies are pursuing, and positioning themselves for partnership or investment.

This report provides a strategic lens for companies looking to get involved early in a market that is anticipated to grow significantly over the coming years by compiling the most pertinent data on pipelines, partnerships, technology platforms, geographic footprints, clinical strategies, and competitive differentiation.

Clinical Trials Insight Included In Report

The report offers a structured and detailed overview of MYC targeted candidates that progress through preclinical and clinical development. Despite the number of compounds that remain in human trials, activity is picking up; likewise, programs are now entering more mature stages. The trials span major global regions such as the United States, Europe, China, and Australia; indications also vary in which MYC amplification, overexpression, or pathway dependency is particularly prominent.

Insights include the therapeutic setting, molecular modality, biomarker strategy, and study design considerations in short, how developers are meeting the inherently high risks of modulating a master regulator. The report further provides insight into the institutional sponsors, academic collaborators, and technology licensors that have been instrumental in driving early translation. Given the highly context dependent nature of MYC biology, these trial level details will help stakeholders assess which approaches are most clinically coherent and commercially viable.

This report allows for further understanding of developmental maturity, pace of progression, and potential inflection points across the global MYC targeting landscape by consolidating dispersed trial information in a unified structure.

Leading Companies Engaged In R&D Of MYC Targeted Therapies

These days, this dynamic field is supported by both established innovators and a growing base of up-and-coming biotech's. Although different strategies have been used, such as direct inhibitors, degraders, transcriptional modulators, and RNA- or oligo based technologies, the common goal is to precisely reduce MYC activity while minimizing toxicity.

The development of structure guided inhibitors, MYC/MAX disruptors, targeted protein degraders, synthetic-lethal methods, and next generation delivery platforms appropriate for intracellular transcription factors are among the companies most actively influencing the market, according to this report. These organizations are working fast to establish partnerships to speed up translation, secure enabling technologies, and develop proof-of-concept datasets.

The investors, partners, and competitors need to understand which companies possess scientific depth, scalable platforms, or differentiated strategic positions at this very nascent stage of the space.

Technology Platforms Included In Report

A key section of the report focuses on enabling technologies that support MYC directed drug development. Among these platforms highlighted is the rapidly emerging class of protein-centric and structure-guided modalities engineered to engage intrinsically disordered proteins-IDPs-a category into which MYC falls and that historically has resisted traditional drug design.

Advanced peptidomimetic systems and targeted degradation technologies, for instance, are showing promising potential in the destabilization of MYC complexes, shifting conformational states, or modulating protein residency on DNA. This provides a platform for developing agents that may be able to engage with MYC in a direct manner, as opposed to relying on pathway level modulation alone.

By cataloging these, the report brings clarity on the technology engines that power pipeline growth and shape competitive differentiation.

Report Indicating Future Direction Of MYC Targeted Therapies Segment

The field should increasingly move towards precise patient stratification, diversified therapeutic modalities, combination strategies, and more-in-depth biological mapping as the targeting of MYC continues to advance. While no MYC targeted therapy has gone through commercialization yet, early successes coming from first-in-human trials and an upward ramping investment are reworking expectations for the decade to come.

The report outlines the developmental trajectories, partnership opportunities, and scientific inflection points emerging to influence the market maturation. It provides a forward-looking analytical framework that will enable stakeholders to navigate a complex but rapidly strengthening therapeutic area-capturing a timely moment of evolution as MYC focused interventions steadily move closer to clinical and commercial reality.

1. Research Methodology

2. Introduction To MYC

2.1 Overview Of MYC In Cancer
2.2 MYC As Therapeutic Target In Oncology

3. MYC: Structure, Evolution, & Role In Cancer

3.1 Structure & Function Of MYC Proteins
3.2 Historical Discovery & Evolution Of MYC As Cancer Target
3.3 Mechanisms Of MYC Dysregulation In Tumorigenesis
3.4 MYC Driven Pathways In Cancer Development

4. Therapeutic Approaches To MYC Targeting

4.1 Direct vs. Indirect MYC Targeting
- 4.1.1 Direct MYC Targeting
- 4.1.2 Indirect MYC Targeting
4.2 Approaches For MYC Targeting
- 4.2.1 Small Molecule Inhibitors
- 4.2.2 Oligonucleotide Based Therapies
- 4.2.3 Targeted Protein Degradation

5. Global MYC Targeting Therapies Clinical Trials Overview

5.1 By Company
5.2 By Country
5.3 By Indication
5.4 By Phase

6. Global MYC Targeting Drugs Clinical Trials Insight By Company, Country, Indication & Phase

6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II
6.5 Phase II

7. MYC Targeting Therapies Development Platforms By Companies

8. MYC Targeting Therapies Development Trends By Indication

8.1 Hematologic Malignancies
8.2 Solid Tumors
8.3 Potential Expansion Into Non-Cancer Indications

9. Global MYC Targeting Therapy Market Scenario

9.1 Current Market Overview
9.2 Future Market Opportunities

10. Global MYC Targeting Therapy Market Dynamics

10.1 Market Drivers & Opportunities
10.2 Market Challenges & Solutions

11. Competitive Landscape

11.1 Genetic Leap
11.2 Curigin
11.3 IDP Pharma
11.4 Incurix
11.5 Omega Therapeutics
11.6 Panavance Therapeutics
11.7 Peptomyc
11.8 Suzhou Kintor Pharmaceuticals
11.9 Wayfinder Biosciences
11.10 WebenPharma

简介目录图表

List of Figures

Figure 2-1: Dual Identity Of MYC In Normal vs. Cancer Cells
Figure 2-2: Challenge Of Drugging MYC
Figure 2-3: Cancer - Upstream Routes That Activate MYC
Figure 2-4: From Barriers To Breakthroughs In MYC
Figure 2-5: Blood Cancers: Ideal Early MYC Targets
Figure 3-1: MYC Family Members - Key Biology
Figure 3-2: Regulatory Roles Of The MYC Box Motifs
Figure 3-3: Expanded Roles Of The Structured C-Terminus Beyond MAX Binding
Figure 3-4: What Makes MYC So Potent
Figure 3-5: MYC Research Evolution
Figure 3-6: Milestones In MYC Discovery & Targeting
Figure 3-7: How Multiple Mechanisms Affect MYC
Figure 3-8: Signaling Pathways Leading To MYC Activation
Figure 3-9: Converging Forces Leading To MYC Driven Malignancy
Figure 3-10: MYC Driven Proliferation & Cell Cycle Control
Figure 3-11: Interconnected Metabolic Effects Of MYC
Figure 3-12: MYC As Central Oncogenic Hub
Figure 4-1: Direct MYC Targeting

Figure 4-2 Indirect MYC Targeting

Figure 4-3: MYC Targeted Small Molecules
Figure 4-4: MYC Targeted Oligonucleotides
Figure 4-5: MYC Targeted Protein Degradation
Figure 5-1: Global - MYC Targeting Therapies Clinical Trials By Company, 2026
Figure 5-2: Global - MYC Targeting Therapies Clinical Trials By Country, 2026
Figure 5-3: Global - MYC Targeting Therapies Clinical Trials By Indication, 2026
Figure 5-4: Global - Number of MYC Targeting Therapies In Clinical Trials By Phase, 2026
Figure 7-1: The Genetic Leap AI stack
Figure 7-2: Transcription Factor-Targeted Drug Discovery Platform - Incurix
Figure 7-3: Bi-specific siRNA - Curigin
Figure 8-1: Hematological Cancer - Regulation Of MYC
Figure 8-2: Solid Tumors - Mechanisms Of MYC Deregulation
Figure 8-3: Solid Tumors - MYC Driven Cellular Programs
Figure 8-4: OMO-103-02 Phase I (NCT06059001) Study - Initiation & Completion Year
Figure 8-5: VHIO23003 Phase 2 (NCT06650514) Study - Initiation & Completion Year
Figure 8-6: GP-2250-1001 Phase I (NCT03854110) Study - Initiation & Completion Year
Figure 8-7: MYC as a Central Regulator in Non-Oncologic Diseases
Figure 9-1: Global MYC Targeting Therapy Market - Future Opportunities
Figure 10-1: Global MYC Targeting Therapy Market - Drivers & Opportunities
Figure 10-2: Global MYC Targeting Therapy Market - Challenges & Solutions